跳至主要内容
临床试验/NCT02954926
NCT02954926已完成3 期

Effect of Intravenous Immunoglobulin in Prevention of Preterm Neonatal Sepsis

Hormozgan University of Medical Sciences1 个研究点 分布在 1 个国家目标入组 92 人开始时间: 2015年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
92
试验地点
1
主要终点
Mortality

研究概览

简要总结

Majority of healthcare authorities believe that due to the methodological weakness and small number of patients in conducted therapeutic trials, the evidences are insufficient to support the efficacy of intravenous immunoglobulin (IVIG) in prevention of preterm neonatal sepsis. The objective of this research is to determine the effect of intravenous immunoglobulin in prevention of preterm neonatal sepsis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Investigator)

入排标准

年龄范围
1 Day 至 7 Days(Child)
性别
All
接受健康志愿者

入选标准

  • Born alive before 37 weeks of pregnancy (preterm neonates)
  • Under 2500 g at birth

排除标准

  • lethal anomaly
  • congenital heart disease
  • TORCH infection
  • severe asphyxia

研究组 & 干预措施

IVIG

Experimental

IVIG at a dose of 500mg/kg within 12 h and 3 days of birth

干预措施: IVIG (Drug)

结局指标

主要结局

Mortality

时间窗: 7 days

Death from sepsis or its related complications

次要结局

  • Total number of days of hospitalization(7 days)
  • Intraventricular Hemorrhage(7 days)
  • Necrotizing enterocolitis(7 days)
  • Bronchopulmonary dysplasia(7 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Hamidreza Mahboobi

Resident of internal medicine

Hormozgan University of Medical Sciences

研究点 (1)

Loading locations...

相似试验